Literature DB >> 33707127

Protein glycation - biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine.

Naila Rabbani1, Paul J Thornalley2.   

Abstract

Protein glycation provides a biomarker in widespread clinical use, glycated hemoglobin HbA1c (A1C). It is a biomarker for diagnosis of diabetes and prediabetes and of medium-term glycemic control in patients with established diabetes. A1C is an early-stage glycation adduct of hemoglobin with glucose; a fructosamine derivative. Glucose is an amino group-directed glycating agent, modifying N-terminal and lysine sidechain amino groups. A similar fructosamine derivative of serum albumin, glycated albumin (GA), finds use as a biomarker of glycemic control, particularly where there is interference in use of A1C. Later stage adducts, advanced glycation endproducts (AGEs), are formed by the degradation of fructosamines and by the reaction of reactive dicarbonyl metabolites, such as methylglyoxal. Dicarbonyls are arginine-directed glycating agents forming mainly hydroimidazolone AGEs. Glucosepane and pentosidine, an intense fluorophore, are AGE covalent crosslinks. Cellular proteolysis of glycated proteins forms glycated amino acids, which are released into plasma and excreted in urine. Development of diagnostic algorithms by artificial intelligence machine learning is enhancing the applications of glycation biomarkers. Investigational glycation biomarkers are in development for: (i) healthy aging; (ii) risk prediction of vascular complications of diabetes; (iii) diagnosis of autism; and (iv) diagnosis and classification of early-stage arthritis. Protein glycation biomarkers are influenced by heritability, aging, decline in metabolic, vascular, renal and skeletal health, and other factors. They are applicable to populations of differing ethnicities, bridging the gap between genotype and phenotype. They are thereby likely to find continued and expanding clinical use, including in the current era of developing precision medicine, reporting on multiple pathogenic processes and supporting a precision medicine approach.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Diabetes; Fructosamine; Glycated hemoglobin; Machine learning; Methylglyoxal

Year:  2021        PMID: 33707127     DOI: 10.1016/j.redox.2021.101920

Source DB:  PubMed          Journal:  Redox Biol        ISSN: 2213-2317            Impact factor:   11.799


  11 in total

1.  Investigation of the Captopril-Insulin Interaction by Mass Spectrometry and Computational Approaches Reveals that Captopril Induces Structural Changes in Insulin.

Authors:  Amrita Ghosh; Aiswarya B Pawar; Tejas Chirmade; Swaraj M Jathar; Rahul Bhambure; Durba Sengupta; Ashok P Giri; Mahesh J Kulkarni
Journal:  ACS Omega       Date:  2022-06-30

Review 2.  Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology.

Authors:  Helmut Sies; Vsevolod V Belousov; Navdeep S Chandel; Michael J Davies; Dean P Jones; Giovanni E Mann; Michael P Murphy; Masayuki Yamamoto; Christine Winterbourn
Journal:  Nat Rev Mol Cell Biol       Date:  2022-02-21       Impact factor: 113.915

3.  Methylglyoxal and glyoxalase 1-a metabolic stress pathway-linking hyperglycemia to the unfolded protein response and vascular complications of diabetes.

Authors:  Naila Rabbani
Journal:  Clin Sci (Lond)       Date:  2022-06-17       Impact factor: 6.876

Review 4.  AGEomics Biomarkers and Machine Learning-Realizing the Potential of Protein Glycation in Clinical Diagnostics.

Authors:  Naila Rabbani
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 5.  Dual Nature of RAGE in Host Reaction and Nurturing the Mother-Infant Bond.

Authors:  Yu Oshima; Ai Harashima; Seiichi Munesue; Kumi Kimura; Nontaphat Leerach; Hisanori Goto; Mariko Tanaka; Akane Niimura; Kenjiro Hayashi; Hiroshi Yamamoto; Haruhiro Higashida; Yasuhiko Yamamoto
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

6.  EGR1 and KLF4 as Diagnostic Markers for Abdominal Aortic Aneurysm and Associated With Immune Infiltration.

Authors:  Chunguang Guo; Zaoqu Liu; Yin Yu; Zhibin Zhou; Ke Ma; Linfeng Zhang; Qin Dang; Long Liu; Libo Wang; Shuai Zhang; Zhaohui Hua; Xinwei Han; Zhen Li
Journal:  Front Cardiovasc Med       Date:  2022-02-09

7.  Advanced Glycation End-Products (AGEs) of Lysine and Effects of Anti-TCR/Anti-TNF-α Antibody-Based Therapy in the LEW.1AR1-iddm Rat, an Animal Model of Human Type 1 Diabetes.

Authors:  Svetlana Baskal; Stefanos A Tsikas; Olga Begou; Alexander Bollenbach; Sigurd Lenzen; Anne Jörns; Dimitrios Tsikas
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

8.  Glycemic control is not related to cerebral small vessel disease in neurologically asymptomatic individuals with type 1 diabetes.

Authors:  Jussi Inkeri; Krishna Adeshara; Valma Harjutsalo; Carol Forsblom; Ron Liebkind; Turgut Tatlisumak; Lena M Thorn; Per-Henrik Groop; Sara Shams; Juha Martola; Jukka Putaala; Daniel Gordin
Journal:  Acta Diabetol       Date:  2021-11-15       Impact factor: 4.280

9.  Fasting Concentrations and Postprandial Response of 1,2-Dicarbonyl Compounds 3-Deoxyglucosone, Glyoxal, and Methylglyoxal Are Not Increased in Healthy Older Adults.

Authors:  Catrin Herpich; Bastian Kochlik; Daniela Weber; Christiane Ott; Tilman Grune; Kristina Norman; Jana Raupbach
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-05-05       Impact factor: 6.591

10.  Special issue on 'Biomarkers of Oxidative Stress, Aging and Nutrition in Human Studies'.

Authors:  Daniela Weber; Tilman Grune
Journal:  Redox Biol       Date:  2021-06-25       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.